AUTHORS
Kathryn Elyse Dickerson, MD, MS, Tamanna Shamrin2, Jessica Uhrich, BA3, Staci Arnold Arnold, MD. MBA, MPH4, Serine Avagyan, MD, PhD5, Deepika Bhatla, MD6, Emi Caywood, MD7, Thomas D. Coates, MD8, Jill de Jong, MD, PhD9, Irem Eldem, MD10, William Ferguson, MD11, Amy Geddis, MD, PhD12, Nicholas Gloude, MD13, Rabi Hanna, MD14, James Huang, MD15, Chibuzo Ilonze, MD, MPH16, Ram Kalpatthi, MD17, Alyssa L. Kennedy, MD, PhD18, Jane Koo, MD19, Elizabeth Krieger, MD20, Harry Layton Lesmana, MD21, Gita Massey, MD22, Julia Meade23, Holly Miller, DO24, Kasiani C. Myers I, MD25, Kathleen Overholt, MD26, Maa-Ohui Quarmyne, MBChB MS27, Jessica Seaborn, MD28, Anjali Sharathkumar, MD, MS29, Franziska Wachter, MD30, Cassandra P Wang, MD31, Timothy S. Olson, MD, PhD32, Akiko Shimamura, MD, PhD33, Taizo Nakano34, Marcin W Wlodarski, MD, PhD35
AFFILIATIONS
1 University of Texas Southwestern Medical Center, Dallas, Texas, United States
2 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
3 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
4 Emory University, Atlanta, Georgia, United States
5 University of California San Francisco, San Francisco, California, United States
6 SSM Health Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States
7 Nemours Children's Health, Newark, Delaware, United States
8 Children's Hospital Los Angeles, Los Angeles, California, United States
9 The University of Chicago, Chicago, Illinois, United States
10 Washington University in Saint Louis, Saint Louis, Missouri, United States
11 SSM Health Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States
12 Seattle Childrens Hospital, Seattle, Washington, United States
13 Rady Children's Hospital-San Diego, San Diego, California, United States
14 Cleveland Clinic Main Campus, Cleveland, Ohio, United States
15 University of California San Francisco, San Francisco, California, United States
16 University of Alabama at Birmingham, Birmingham, Alabama, United States
17 Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
18 St Jude Childrens Research Hospital, Memphis, Tennessee, United States
19 Children's Hospital Medical Center, Cincinnati, Ohio, United States
20 Virginia Commonwealth University, Richmond, Virginia, United States
21 Cleveland Clinic Main Campus, Cleveland, Ohio, United States
22 Virginia Commonwealth University, Richmond, Virginia, United States
23 Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
24 Phoenix Children's Hospital, Phoenix, Arizona, United States
25 Children's Hospital Medical Center, Cincinnati, Ohio, United States
26 Riley Children's Health Indiana University Health, Indianapolis, Indiana, United States
27 Phoenix Children's Hospital, Phoenix, Arizona, United States
28 Riley Children's Health Indiana University Health, Indianapolis, Indiana, United States
29 University of Iowa Health Care, Iowa City, Iowa, United States
30 Boston Children's Hospital, Boston, Massachusetts, United States
31 Children's Hospital Los Angeles, Los Angeles, California, United States
32 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
33 Boston Children's Hospital, Boston, Massachusetts, United States
34 Children's Hospital Colorado, Denver, Colorado, United States
35 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
ABSTRACT
Background: Pediatric bone marrow failure (BMF) and myelodysplastic syndromes (MDS) are heterogeneous group of disorders with complex clinical presentations and genetic origins. Due to their rarity, multicenter collaborations are essential for clinically meaningful analyses. Despite advances in molecular diagnostics and treatment approaches, no comprehensive national registry for pediatric MDS has existed in the United States. Here we describe the systematic development of a national multicenter registry for retro/prospective BMF/MDS enrollment and provide data focusing on MDS patients.
Objective: The North American Pediatric Aplastic Anemia Consortium (NAPAAC) Registry was established to characterize clinical manifestations, genetic characteristics, and outcomes in pediatric BMF/MDS. For this purpose, we created an online registry using a RedCap Cloud system where each site maintains data ownership within a federated registry structure.
Design/Method: Registry development spanned two years (2021–2023) and included IRB protocol implementation, consensus-driven variable definition, development of 18 electronic case report forms (CRFs) across three domains Patient Essential Data (demographics, diagnostics, genetics), Therapy and Surveillance (interventions, outcomes), and Specialized Tracking (infectious complications, follow-up); creation of a comprehensive data dictionary; instructional videos and a dedicated registry website; technical validation through alpha testing; and multisite beta-testing prior to final deployment (12/2023). To assist users in onboarding and data entry, a weekly virtual help desk was held for 6 months The pediatric MDS registry is one of two currently supported active projects. The modular design allows the addition of new project-specific case report forms as needed.
Results: By July 2026, registry infrastructure included thirty-six IRB-approved sites with 118 active users across all US mainland time zones. Twenty-one centers contributed to MDS data collection, enrolling 508 patients in the MDS cohort, but only 363 patients who were confirmed to have an MDS diagnosis per the 2022 WHO/ICC classification. Diagnoses included MDS without excess blasts (n=208; 57.3%), MDS with excess blasts (n=125; 34.4%), MDS/acute myeloid leukemia or AML overlap including AML with myelodysplasia related changes or MRC (n=19; 5.2%), myeloproliferative neoplasms or MPN (n = 6; 1.7%) and clonal hematopoiesis or CH (n = 5; 1.4%). Patients with germline predisposition to MDS that had not yet developed hematologic malignancy were also enrolled.
The MDS cohort’s diagnoses span past 30 years, with 248 (60.0%) of the MDS cases being diagnosed only within the past 10 years (2016-2026) and 157 cases (38.3%) in the preceding 10 years (2006-2016). The MDS cohort includes 57.5% males and 65.3% White patients, with a median age at diagnosis of 10 years (Interquartile range or IQR 5–15 years).
Genetic testing of some form was performed in 85.8% of patients. Among patients without manifestation of hematologic malignancy, ninety-seven cases harbor a known germline/genetic predisposition. Among patients diagnosed with a hematologic malignancy (MDS, MDS/AML, MPN, and CH), 26% (n = 93/366) have/had an identified genetic syndrome. Predominant germline genes affected in this cohort are GATA2, RUNX1, SAMD9, SAM9L in addition to genes causing Fanconi anemia, Shwachman-Diamond syndrome, and telomere biology disorders.
At last follow-up, 71.6% of patients were alive, 58.6% of patients were confirmed to have undergone hematopoietic stem cell transplantation, and the median age at last follow up was 15 years (IQR 10-20 years).
Conclusion: We established the first national multicenter pediatric MDS cohort with comprehensive clinical and genetic data harmonized across 36 active sites under a single IRB-aligned federated data-ownership framework. Active projects include MDS and genetic neutropenias, with several additional projects onboarding in the coming year. This collaborative resource will enable future studies aimed at improving diagnosis, treatment, and outcomes in these rare disorders. Beyond characterizing MDS, the registry provides a longitudinal resource for studying individuals with germline predisposition who are at risk for hematologic malignancy.
DISCLOSURES
Kathryn Elyse Dickerson, MD, MS: Genetix - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony)